Humacyte, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 36.97 million compared to USD 19.83 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.19 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.34 USD | +5.01% | +10.04% | +158.45% |
06-03 | Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing | MT |
05-30 | Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+158.45% | 832M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023